about
Protein Quality Control and the Amyotrophic Lateral Sclerosis/Frontotemporal Dementia ContinuumRole of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy.Valproate Attenuates 25-kDa C-Terminal Fragment of TDP-43-Induced Neuronal Toxicity via Suppressing Endoplasmic Reticulum Stress and Activating Autophagy.Molecular epigenetics in the management of ovarian cancer: are we investigating a rational clinical promise?c-Jun Amino-Terminal Kinase is Involved in Valproic Acid-Mediated Neuronal Differentiation of Mouse Embryonic NSCs and Neurite Outgrowth of NSC-Derived Neurons.Animal models of monogenic migraine.The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.Restoration of Megalin-Mediated Clearance of Alveolar Protein as a Novel Therapeutic Approach for Acute Lung Injury.Valproate induced hyperammonemic encephalopathy treated by haemodialysis.Valproate induced hyperammonemic encephalopathy treated by haemodialysis.Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells.Valproic Acid Arrests Proliferation but Promotes Neuronal Differentiation of Adult Spinal NSPCs from SCI Rats.Valproic acid (VPA) inhibits the epithelial-mesenchymal transition in prostate carcinoma via the dual suppression of SMAD4.Valproic acid preserves motoneurons following contusion in organotypic spinal cord slice culture.Effects of Two-by-Two Combination Therapy with Valproic Acid, Lithium Chloride, and Celecoxib on the Angiogenesis of the Chicken Chorioallantoic Membrane
P2860
Q33653996-550D7F53-48D7-437C-95D8-883BC919F9A6Q35676378-5E022F9B-5AED-407C-9566-CF3680D4B5DBQ35739624-C7502EF9-E031-4FB2-A48E-EE6507928C82Q37702543-CB2DAE7F-9241-404B-8C98-22680D8A13B0Q37732914-16B6445E-2F12-40BA-BED2-6E4D556D2C64Q38828065-2D727544-3F5C-4CC1-82BC-04C80D0EDA30Q38879058-D8D35171-AA43-41F1-B897-73CAA5E82FD4Q47842866-CD4A676D-CDF4-434B-9EC0-E06DDFBE2C85Q49702357-C1BF63C6-5D8A-492B-97FF-5855515D2A73Q49885815-DC290330-BAE6-4651-89FF-7B83DCBD74C3Q52868783-142AE9E1-C0A5-4D72-BD9F-8364AAAE9D04Q52940214-091370D1-6457-4426-91F6-6C9F25382E80Q53410584-BE070AB8-8DDA-472E-AE94-E28E7DDB94B9Q53736174-D39F8592-BD48-43EA-9922-D7D8D8DE9FB2Q58776363-9D91AB1A-1958-40F5-A10A-103521B054AE
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
New perspectives of valproic acid in clinical practice.
@ast
New perspectives of valproic acid in clinical practice.
@en
New perspectives of valproic acid in clinical practice.
@nl
type
label
New perspectives of valproic acid in clinical practice.
@ast
New perspectives of valproic acid in clinical practice.
@en
New perspectives of valproic acid in clinical practice.
@nl
prefLabel
New perspectives of valproic acid in clinical practice.
@ast
New perspectives of valproic acid in clinical practice.
@en
New perspectives of valproic acid in clinical practice.
@nl
P2860
P1476
New perspectives of valproic acid in clinical practice
@en
P2093
Lenka Činčárová
Zbyněk Zdráhal
P2860
P304
P356
10.1517/13543784.2013.853037
P407
P50
P577
2013-10-28T00:00:00Z